Equity Research
William Blair research analyst Sami Corwin was quoted in MedCity News following the acquisition of Legend Biotech by Novartis, a move focused on cell therapy for solid tumors.
“The deal is an ‘incremental positive’ for Legend, allowing the company to monetize its DLL3 program earlier in development,” Corwin wrote in the note to investors that was quoted by the publication.
Stay up-to-date with the latest William Blair news and insights
William Blair initiated research coverage of First Advantage Corporation (FA $15.32), a leading global provider of technology-enabled background screening products.
Read moreWilliam Blair initiated research coverage of On Holding AG (ONON $32.87), a fast-growing performance and lifestyle brand based in Switzerland selling athletic footwear, primarily in running, but with a growing presence in newer categories and apparel.
Read moreWilliam Blair initiated research coverage of Cullinan Oncology, Inc. (CGEM $17.37), a company focused on advancing modality-agnostic targeted therapies for cancer, with a broad pipeline encompassing small molecules and multifunctional therapies across a diverse range of oncologic targets.
Read moreInformation contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.
For disclosure information, please visit www.williamblair.com/disclosures
